SMMT Research and Charts

SMMT - Summit Therapeutics Inc Ordinary Shares (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-12 (Delayed quote data 2025-01-06)

Last 17.47	Change ⇓ -0.77 (-4.22%)	Volume 2,067,970
	Open 18.33	High 18.51	Low 17.41

8EMA (Daily) 18.09	40EMA (Daily) 18.60	50EMA (Daily) 18.60	STO (Daily) 41.544	MACD Hist (Daily) -0.054
8EMA (Weekly) 18.241	40EMA (Weekly) 14.47	50EMA (Weekly) 13.20	STO (Weekly) 14.056	MACD Hist (Weekly) -1.320


Company Profile
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has three geographical segments: United States, Latin America, and Europe.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.